If your pathology report says your breast cancer is hormone-receptor-positive, or that it is triple-negative, it is describing which “receptors” — docking points for hormones and growth signals — the cancer cells have. Hormone-receptor-positive cancers carry receptors for estrogen, progesterone, or both. Triple-negative cancers have none of the three receptors doctors routinely test for. That difference matters, because it shapes which treatments your care team is likely to discuss with you.
Key Takeaways
- “Hormone-receptor-positive” means the cancer cells have receptors for estrogen, progesterone, or both, and hormones can help those cells grow.
- “Triple-negative” means the cancer tests negative for estrogen receptors, progesterone receptors, and the HER2 protein.
- Both results come from laboratory tests on a sample of the tumor, reported in your pathology report.
- The receptor results help doctors decide which kinds of treatment to discuss; hormone therapy is an option only for hormone-receptor-positive cancers.
- Neither label by itself tells you how your own case will unfold — stage, grade, and your overall health matter too, and your care team can explain the whole picture.
What Receptors Are, in Plain Language
A receptor is a protein on or inside a cell that works a little like a docking point. When the right substance — for example, the hormone estrogen — connects with its receptor, it can send the cell a signal to grow and divide. Many healthy breast cells have hormone receptors, and some breast cancers keep them. Doctors test every breast cancer for three things: estrogen receptors (ER), progesterone receptors (PR), and a growth-related protein called HER2. The pattern of results is one of the main ways breast cancers are grouped, as our complete guide to the types of breast cancer compared explains.
The comparison in this article sets the two most talked-about patterns side by side: cancers that have hormone receptors, and cancers that have none of the three markers. A cancer can also be hormone-receptor-positive and HER2-positive at the same time, so these labels can overlap rather than sit in neat separate boxes.
What Hormone-Receptor-Positive Means
A cancer is called hormone-receptor-positive when laboratory testing finds estrogen receptors, progesterone receptors, or both on the cancer cells. You may see it written as ER-positive, PR-positive, or “hormone-receptor-positive” in your report. It means estrogen, progesterone, or both can encourage those cells to grow.
This is helpful information, because a cancer that depends on hormones can often be treated by blocking that supply or that signal. Treatments that do this are grouped under the name hormone therapy (sometimes called endocrine therapy). Knowing a cancer is hormone-receptor-positive is what makes that whole category of treatment worth discussing. Our separate guide to hormone-receptor-positive breast cancer explained goes through this result in more depth.
What Triple-Negative Means
Triple-negative breast cancer is defined by what it does not have. The cells test negative for estrogen receptors, negative for progesterone receptors, and negative for HER2. Because none of the three standard docking points are present, hormone therapy and HER2-targeted treatments do not work against it, and doctors rely on other kinds of treatment instead.
The name can sound alarming, but it is simply a description of the test results, not a prediction about you personally. Triple-negative cancers are a varied group, and two people with the same label can have different stages, different grades, and different treatment plans. Our guide to triple-negative breast cancer explained covers how this type is usually approached.
The Two Side by Side
| Feature | Hormone-receptor-positive | Triple-negative |
|---|---|---|
| Estrogen/progesterone receptors | Present (one or both) | Absent |
| HER2 | Can be positive or negative | Negative |
| Can hormones fuel growth? | Yes, estrogen and/or progesterone | No |
| Hormone therapy an option? | Yes, usually discussed | No |
| HER2-targeted therapy an option? | Only if also HER2-positive | No |
| Other treatments discussed | Surgery, radiation, chemotherapy, and targeted medicines depending on the case | Surgery, radiation, chemotherapy, and in some cases immunotherapy or other targeted medicines |
Treat this table as a map of the conversation, not as your treatment plan. Which of these options is actually raised with you depends on the stage and grade of the cancer, whether lymph nodes are involved, your age and general health, and your own preferences after hearing the benefits and downsides of each path.
How Doctors Test for Receptors
Receptor testing is done in a laboratory on a small sample of the tumor, usually from the biopsy that confirmed the diagnosis, and sometimes repeated on tissue removed during surgery. The results appear in your pathology report as “positive” or “negative” for each marker, and hormone receptor results may also include a percentage or a score describing how many cells tested positive and how strongly. Testing is standard for breast cancer; our guide to ER, PR, and HER2 testing explained walks through how the tests are performed.
Occasionally a result is borderline or unclear, and the laboratory may repeat the test or test a different sample. If your report language is hard to follow, you are entitled to ask your team to go through it line by line — our guide to understanding your breast cancer pathology report can help you prepare for that conversation.
How the Difference Shapes Treatment Discussions
For a hormone-receptor-positive cancer, hormone therapy is usually part of the discussion. It works by lowering estrogen in the body or by blocking estrogen from connecting with the cancer cells, and it is commonly given after surgery to reduce the chance of the cancer returning, sometimes for a period of years. Depending on the case, doctors may also discuss surgery, radiation, chemotherapy, and certain targeted medicines.
For a triple-negative cancer, the conversation usually centres on surgery, radiation, and chemotherapy, because those are the tools that work regardless of receptors. In some situations, doctors may also discuss immunotherapy or other targeted treatments, including for people whose cancer carries certain inherited gene changes. Which of these applies is a case-by-case judgment, and recommendations change as research develops, so current guidance is published by organizations such as the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov).
One point is worth holding onto: a treatment not being mentioned does not mean your team is withholding something. Each label simply opens some doors and closes others, and a good team will explain why the plan they propose fits your particular results.
Questions to Ask Your Doctor
- What exactly do my ER, PR, and HER2 results say, and can you show me where they are in my report?
- Is my cancer considered hormone-receptor-positive, triple-negative, or a combination?
- Which treatments does this result make relevant for me, and which does it rule out?
- How do the stage and grade of my cancer affect the plan alongside the receptor results?
- Should my sample be retested, or should I consider genetic testing as well?
- Where can I read more from a trusted source before I decide anything?
Frequently Asked Questions
Can a cancer be hormone-receptor-positive and triple-negative at the same time?
No. Triple-negative means all three markers — estrogen receptors, progesterone receptors, and HER2 — are absent. A cancer with estrogen or progesterone receptors present is hormone-receptor-positive by definition, whatever its HER2 result.
Is one of these types “better” or “worse” than the other?
Neither label is simply better or worse. Hormone-receptor-positive cancers have an extra treatment option in hormone therapy, while triple-negative cancers often respond well to chemotherapy. What matters most for any individual is the full picture — stage, grade, and how the cancer behaves — which your care team can put together for you.
Why does my report give a percentage for estrogen receptors?
Laboratories report how many of the cancer cells tested positive, and how strongly, because even a small amount of hormone receptor activity can make hormone therapy worth discussing. Your team can explain what your particular percentage means for your plan.
Can receptor results change over time?
They can occasionally differ between the original biopsy and later samples, or if the cancer returns. That is one reason doctors sometimes retest tissue. If your situation changes, ask whether repeat testing would be useful in your case.
Does triple-negative mean my cancer was caused by something I did?
No. Receptor status is a property of the cancer cells themselves, not something caused by diet, habits, or anything you did or failed to do. Nothing about this result is your fault.
Related Articles
- Types of Breast Cancer Compared: The Complete Guide
- Triple-Negative vs HER2-Positive Breast Cancer: How They Differ
- Hormone-Receptor-Positive Breast Cancer Explained
- Triple-Negative Breast Cancer Explained
- ER, PR, and HER2 Testing Explained
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.